Latest Medtech News
Dialybrid S.r.l., an Italian medical device company based in Cantù, has closed a €15 million Series A round led by new investor XGEN Venture, with participation from CDP Venture Capital's Rilancio Fund. Alongside the raise, the company announced the successful first-in-human implant of its Silkothane Arteriovenous Graft, a novel vascular access device for hemodialysis patients with end-stage kidney disease.
As an executive search partner to the MedTech industry, Guided Solutions keeps a close eye on stories like this one. Subscribe to our Industry Insights for weekly coverage.
The implant was performed by coordinating principal investigator Prof. Matteo Tozzi, Director of the Vascular Surgery Department at ASST Sette Laghi and Professor of Vascular Surgery at Insubria University in Varese, Italy, as part of a first-in-human trial enrolling up to 18 adult patients across four Italian centers. The open-label, single-arm study will track safety and performance for up to 60 months, with interim analyses at 6, 12, and 24 months.
Silkothane is a patented hybrid material combining silk fibroin, a biocompatible, bioresorbable substance that supports tissue remodeling, with polyurethane, a durable synthetic material, manufactured via electrospinning. The company positions the graft as addressing a persistent clinical gap: an estimated 60% of synthetic arteriovenous grafts and 40% of native arteriovenous fistulas fail within their first year, despite more than half a million vascular access procedures performed annually across the EU and US for hemodialysis patients.
For Dialybrid, the funding supports continued clinical development of the graft toward regulatory approval, along with preclinical work applying Silkothane to other vascular applications. For the broader MedTech space, the deal adds to continued investment in addressing longstanding durability and infection challenges in vascular access, a foundational but underserved area of kidney care technology.
CEO Francesco Giovanni Greco called the milestone "transformative" for the company, while Prof. Tozzi described the ease of the first implant as encouraging for a device that could offer "shorter cannulation time than native fistulas and longer durability than commercially available grafts."
